# CP-10

| | |
|---|---|
| **Cat. No.:** | HY-125835 |
| **CAS No.:** | 2366268-80-4 |
| **Molecular Formula:** | $C_{44}H_{49}N_{13}O_7$ |
| **Molecular Weight:** | 871.94 |
| **Target:** | PROTAC; CDK |
| **Pathway:** | PROTAC; Cell Cycle/DNA Damage |
| **Storage:** | -20°C, stored under nitrogen<br>* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 200 mg/mL (229.37 mM; Need ultrasonic)

| Preparing Stock Solutions | Concentration / Solvent / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 1.1469 mL | 5.7343 mL | 11.4687 mL |
| | 5 mM | 0.2294 mL | 1.1469 mL | 2.2937 mL |
| | 10 mM | 0.1147 mL | 0.5734 mL | 1.1469 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

CP-10 is a PROTAC with highly selective, specific, and remarkable CDK6 degradation ($DC_{50}$=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6[1].

| $IC_{50}$ & Target | | |
|---|---|---|
| | CDK6<br>2.1 nM (DC50) | Cereblon |

**In Vitro**

CP-10 induces nearly 72% degradation of CDK6 at 10 nM and 89% at 100 nM in human glioblastoma U251 cells. The degradation of CDK4 induced by CP-10 is far weaker than that of CDK6 ($DC_{50}$: 50-80 fold)[1].

CP-10 displays a cell inhibition potential in multiple myeloma cell MM.1S ($IC_{50}$≈10 nM) and mantle cell lymphoma cells (in Mino, $IC_{50}$≈8 nM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Su S, et al. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 2.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA